article thumbnail

Cell and gene therapy approvals drive paradigm change in manufacturing

Pharmaceutical Technology

Trends in gene therapy approvals in recent years are rapidly shaping the future of manufacturing capabilities in the pharmaceutical industry.

article thumbnail

Regeneron confirms FDA won’t approve myeloma drug over manufacturing issues

Bio Pharma Dive

Company executives had previously warned investors that a delay was likely due to issues at a facility run by third-party manufacturer.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Gene therapy biotech Jaguar spins out manufacturing company

Bio Pharma Dive

Called Advanced Medicine Partners, the new company will offer specialized cell and gene therapy manufacturing services to biotech and pharma clients.

article thumbnail

Injectables manufacturing ushers in a new era of accessibility

Pharmaceutical Technology

Increasingly, injectable manufacturers recognise that to achieve maximum profitability, they need to focus on the value they provide.

article thumbnail

Making the Case for Case Management for Cell and Gene Therapies

A dedicated Case Manager provides end-to-end supply chain management and 24/7 oversight and support to help ensure the seamless manufacturing and distribution of each therapy dose to every patient.

article thumbnail

GSK invests $800M in manufacturing; Amgen sets small discount for Eylea biosimilar

Bio Pharma Dive

manufacturing investment. The British pharma is making what it calls its largest U.S. Elsewhere, AbbVie expanded a longstanding partnership and Marinus said it would lay off staff.

article thumbnail

German CDMO outlays $980m on GLP-1 manufacturing expansion

Pharmaceutical Technology

As the EU anticipates GLP-1RA shortages throughout 2024, Corden Pharma has pledged $980m to increase manufacturing capacity.

article thumbnail

Roles and Responsibilities of Specialized Clinical Supply Experts

When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial.